NATIVA PRENATAL

NATIVA PRENATALE

The Test of non-invasive prenatal screening capable of identifying the main chromosomal abnormalities present in the fetus and the gender of the unborn child

NATIVA is the non-invasive prenatal test clinically validated on thousands of pregnancies, it provides precise and punctual information on the aneuploidies of all chromosomes, chromosome deletions and duplications of size ≥ 7 Mb and six microdeletions.

NATIVA, thanks to the greater sensitivity and specificity compared to conventional screening tests, decreases the use of invasive diagnostic tests, reducing the risk of miscarriage related to them.

Si esegue con un prelievo di sangue materno, attraverso il quale è possibile analizzare i frammenti del DNA fetale circolante.


NATIVA può essere effettuato a partire dalla 10a settimana di gestazione e, a differenza dei test diagnostici invasivi, non presenta rischi per la mamma e per il bambino.

To book NATIVA PRENATALE send a mail to customerservice@xbiogem.it

BOOK YOUR TEST
NOW!

What does it analyze

FIND OUT WHAT IT ANALYZES
  • Trisomies 21, 18, 13;
  • Sex chromosome aneuploidies (XXX, XO, XXY, XYY);
  • Fetal sex analysis;
  • For single and twin pregnancies;
  • CE/IVD Certification;

    • Analysed at the BioRep laboratories, in Italy

    FIND OUT WHAT IT ANALYZES
  • Trisomies 21, 18, 13;
  • Sex chromosome aneuploidies (XXX, XO, XXY, XYY);
  • Microdeletions (22q 11.2, 1p 36, 15q 11.2, 5p 15.3, 4p 16.3);
  • Fetal sex analysis;
  • Only for singleton pregnancies;

    • Analysed at the BioRep laboratories, in Italy

    logo
    FIND OUT WHAT IT ANALYZES
  • Trisomies 21, 18, 13;
  • Sex chromosome aneuploidies (XXX, XO, XXY, XYY);
  • Aneuploidies of all autosomal chromosomes (RAAs);
  • Microdeletions (22q 11.2, 1p 36, 15q 11.2, 5p 15.3, 4p 16.3);
  • Fetal sex analysis;
  • Only for singleton pregnancies;

    • Analysed at the BioRep laboratories, in Italy

    FIND OUT WHAT IT ANALYZES
  • Aneuploidy 21, 18 and 13;
  • Sex chromosome aneuploidies (XXX, XO, XXY, XYY);
  • Aneuploidies of all autosomal chromosomes (RAAs);
  • Partial deletions and duplications ≥ 7Mb on all chromosomes (CNVs);
  • Fetal sex analysis;
  • For single and twin pregnancies;
  • CE/IVD Certification;

    • Analysed at the BioRep laboratories, in Italy

    How does it work

    logo

    F.A.Q. - NATIVA PRENATAL

    The test is indicated in case of:

  • At-risk pregnancy in which invasive prenatal diagnosis is contraindicated;
  • Pregnancy in which the combined test (PAPP-A and hCG levels + nuchal translucency) provides a risk of chromosomal abnormality;
  • Pregnant women with previous miscarriages;
  • Family history of chromosomal aneuploidies;

    • It can also be performed in case of:

  • Twin pregnancy;
  • Pregnancy from assisted fertilization (homologous or heterologous);

    • The NATIVA test is not a substitute for invasive prenatal diagnosis, such as amniocentesis and CVS, but it is a screening test whose results must be evaluated in the context of the clinical picture and anamnestic of the pregnant woman.

    The test does not detect the state of health of the mother and is not able to highlight the alterations of the chromosomes not analyzed, the balanced and unbalanced structural chromosomal rearrangements, the polyploidies.

    The test should be included in a pregnancy path agreed with your doctor.

    The case of twin pregnancies:

  • Does not analyze sex chromosome aneuploidies
  • In the event of a positive outcome, it is unable to discriminate which of the two fetuses is affected
  • Only detects the presence or absence of the Y chromosome.

    • The test is NOT recommended in case of:

  • Vanishing twin or evanescent twin
  • Multiple pregnancies with more than two fetuses
  • Pregnant woman known to have cancer
  • Immunotherapy, radiotherapy or blood transfusion performed by the pregnant woman within the previous 3 months
  • Allogeneic organ transplantation in the pregnant woman

    • The NATIVA test is performed on a simple maternal blood sample, it is non-invasive and does not involve any risk for the pregnant woman and the child. NATIVA analyzes the fragments of fetal DNA that circulate freely in maternal blood. The procedure is simple and the result is obtained in 5/12 working days from receipt of the sample at the laboratory.

    For the NATIVA and NATIVA NEXT tests it takes 5 working days from when the sample arrives in the laboratory, while for the NATIVA PLUS and NATIVA KARYON tests it takes 10-12 working days from when the sample reaches the laboratory.

    NATIVA PLUS and NATIVA KARYON analyze the presence of microdeletions, structural anomalies of the chromosomes caused by the loss of small portions of DNA. Some microdeletions are specific to well-characterized chromosomal regions and are associated with particular syndromes. Microdeletion syndromes are clinically recognizable pathologies, characterized by a peculiar phenotype, and include the syndromes listed in the table.

    logo

    Rare Autosomal Aneuploidies (RAAs) are numerical alterations (presence of one chromosome more or less than the normal karyotype human) that can occur in all chromosomes. Partial duplications and deletions (CNVs) are chromosomal abnormalities that have more or less DNA portions than the normal karyotype and can occur in any chromosomal region.

    NATIVA NEXT analyzes all RAAs and CNVs >7Mb in size

    The incidence of RAAs in early pregnancy is estimated at 0.34%. The incidence of CNVs >7Mb is estimated at 0.10% which together with RAAs (0.34%) make up 0.44% of the incidences of total chromosomal conditions. Compared to 0.50% of the estimated incidence of the most common trisomies 21, 18, 13.

    It is possible to request the reimbursement in the form of indirect compensation, however it is advisable to first check the reimbursement of the service with your health insurance company.

    You can contact XBIOGem on +39 06 3015 8224 Monday to Thursday from 8:30 to 16:00 and Friday from 8:30 to 14:00.

    Condividi su